(BCYC) Bicycle Therapeutics plc BCG Matrix Research |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
(BCYC) Bicycle Therapeutics plc Complete Analysis Pack
Visual. Strategic. Downloadable.
This Bicycle Therapeutics plc BCG Matrix is a company-specific strategic tool used to assess the business portfolio across Stars, Cash Cows, Question Marks, and Dogs for planning, research, and investment analysis. What you see on this page is a real preview of the actual report content, so you can review the format and quality before buying. Purchase the full version to get the complete ready-to-use analysis.
Stars
BT8009, Phase I/II, Nectin-4 BTC
BT8009 is Bicycle Therapeutics’ lead disclosed oncology asset and the clearest Star in its BCG mix. This Phase I/II Nectin-4 Bicycle Toxin Conjugate targets a validated solid-tumor marker already proven by enfortumab vedotin, which generated about $1.8 billion in 2024 sales. That gives BT8009 both clinical maturity and a large, fast-growing urothelial cancer opportunity.
BT5528, Phase I/II, EphA2 BTC
BT5528 is Bicycle Therapeutics plc’s Phase I/II EphA2 BTC and a clear Star in the BCG mix. EphA2 is overexpressed across multiple solid tumors, including lung, breast, and head and neck cancers, so the commercial pool is broad. Continued clinical progress keeps it among the highest-priority pipeline assets.
BT1718, Phase I/IIa, MT1-MMP BTC
BT1718 is one of Bicycle Therapeutics plc’s earlier named clinical BTC assets, and its Phase I/IIa MT1-MMP target gives it first-mover value in a tumor-targeted setting with clear unmet need. In Bicycle Therapeutics plc’s FY2025 reporting, it remained an early pipeline program, with no product revenue yet disclosed. If development momentum holds, BT1718 can help seed future franchise growth.
BT7480, Nectin-4 TICA
BT7480, Bicycle Therapeutics plc’s Nectin-4 TICA, fits the Stars box: it targets a validated cancer marker and taps immune-oncology, a market forecast by many analysts to keep growing at double-digit rates through 2026. Nectin-4 is already de-risked as a target, so this looks like a strong platform-extension asset if clinical data stay clean.
- Validated target: Nectin-4
- Fast-growing IO category
- Platform-extension upside
- High strategic relevance
THR-149, completed Phase II, diabetic macular edema
THR-149 is Bicycle Therapeutics plc’s most advanced non-oncology asset and a clear Star candidate if it keeps advancing after Phase II in diabetic macular edema (DME). DME affects millions worldwide and sits in a large ophthalmology market where anti-VEGF resistance leaves real unmet need. A positive late-stage readout could give Bicycle a second growth engine beyond cancer.
- Most advanced non-oncology program
- DME has high unmet need
- Could diversify Bicycle beyond oncology
Bicycle Therapeutics' Star Assets Target Big, Growing Markets
Bicycle Therapeutics plc’s Stars are BT8009, BT5528, BT7480, and THR-149: each sits in a large, high-growth market with clear target validation or clinical need. BT8009 and BT7480 both target Nectin-4, a de-risked cancer marker tied to enfortumab vedotin’s about $1.8 billion 2024 sales, while THR-149 could open a second growth lane in DME.
| Asset | Star signal |
|---|---|
| BT8009 | Nectin-4; large urothelial market |
| BT5528 | EphA2; broad solid-tumor reach |
| BT7480 | Nectin-4; IO platform upside |
| THR-149 | DME; non-oncology growth |
What is included in the product
Detailed Word Document
Bicycle Therapeutics plc BCG Matrix maps pipeline units by growth and share, highlighting invest, hold, and divest priorities.
Editable Excel File
One-page Bicycle Therapeutics plc BCG Matrix mapping that clarifies portfolio pain points fast for easy decision-making
Reference Sources
Provides a concise source trail for Bicycle Therapeutics plc, boosting credibility and helping decision-makers verify key claims quickly.
Cash Cows
Genentech collaboration, multiple immuno-oncology targets
Genentech gives Bicycle Therapeutics plc a rare non-dilutive funding stream: the 2019 deal included $30 million upfront and up to $1.7 billion in milestone payments, plus tiered royalties.
That backing helps fund target discovery and development across multiple immuno-oncology programs without Bicycle bearing the full commercial cost.
In BCG terms, this is the closest thing to a cash cow stream: low capital drain, outside partner risk, and upside tied to every new target.
AstraZeneca collaboration
The AstraZeneca collaboration sits in Bicycle Therapeutics plc’s Cash Cows bucket because it gives Bicycle Therapeutics plc non-dilutive cash from a major pharma partner. These deals usually include upfront fees, milestone payments, and fully funded research, so Bicycle Therapeutics plc can keep more capital for its own pipeline. The result is steady cash inflow without giving up control of core assets.
Sanofi collaboration
Sanofi is a Cash Cow style partnership for Bicycle Therapeutics plc because it can fund R&D without relying on product sales. The value comes from upfront, license, and milestone payments, so it is steadier and lower growth than Bicycle Therapeutics plc’s clinical pipeline. This kind of large-partner deal can act as non-dilutive funding and reduce burn pressure.
Cancer Research UK and Cancer Research Technology agreement
The Cancer Research UK and Cancer Research Technology deal is a cash cow for Bicycle Therapeutics plc: it pairs academic-linked licensing with clinical support, so the company can fund discovery without leaning on self-funded product bets. These ties also validate the Bicycle platform in external research settings, which helps lower development risk. One clean signal: this is support income, not a growth-burning spend line.
- Funds early discovery work
- Validates the Bicycle platform
- Uses non-dilutive support capital
Oxurion and Dementia Discovery Fund collaborations
Oxurion and Dementia Discovery Fund collaborations fit the Cash Cows label because they can bring in research fees and milestone payments from outside partners while Bicycle Therapeutics keeps commercial overhead low. In a still-precommercial model, that kind of partner-funded science can be a steady cash bridge, even if it is not the main growth engine.
- Partner-led, low-overhead funding
- Research fees plus milestones
- Fits precommercial cash generation
Big Pharma Deals Fuel Bicycle Therapeutics’ Growth
Bicycle Therapeutics plc’s Cash Cows are its partner deals, led by Genentech, AstraZeneca, Sanofi, and research groups. The Genentech pact brought $30 million upfront and can reach $1.7 billion in milestones, plus royalties, so it adds non-dilutive cash with low capital strain.
These collaborations help fund R&D without full commercial burn, which fits a Cash Cow role in a precommercial business.
| Partner | Cash support |
|---|---|
| Genentech | $30M upfront, up to $1.7B milestones |
| AstraZeneca | Upfront and milestone cash |
| Sanofi | Upfront and milestone cash |
Preview Before You Purchase
Bicycle Therapeutics plc Reference Sources
You’re previewing the exact Bicycle Therapeutics plc BCG Matrix document you’ll receive after purchase. The full file is the same professionally formatted report, with no hidden changes, demo content, or watermarks. Once purchased, it’s ready to download, use, and share right away.
Dogs
0 approved products
In FY2025, Bicycle Therapeutics still had 0 approved products and no marketed drug franchise, so there is no low-share commercial asset to harvest. In BCG terms, that means it has not built a true Dog segment yet. The story remains clinical-stage execution, not product harvesting.
0 recurring product sales
In FY2025, Bicycle Therapeutics plc still had no approved product revenue, so recurring product sales were 0. With no sales base, there is no low-growth commercial unit absorbing marketing or distribution spend. The risk sits in R&D burn and pipeline execution, not product drag.
0 mature brands
Dogs are effectively 0 mature brands for Bicycle Therapeutics plc: it has no approved, legacy products with a stable market share. As of FY2025, value still depends on pipeline execution and partner deals, not on recurring brand sales. With no mature, low-growth franchises, this BCG bucket stays empty.
0 market-share leadership in commercial drugs
As of FY2025, Bicycle Therapeutics plc has no approved medicines and no commercial sales, so it holds 0% share in any approved drug market. Its assets are still in clinical development, so any "share" is measured by trial progress, not revenue. That means there is no true market-share dog to cut from the portfolio.
- No approved products
- 0% commercial drug share
- Development-stage only
0 divestiture-ready commercial units
Bicycle Therapeutics plc has 0 divestiture-ready commercial units, because it has no approved products or mature product line to sell. In its latest reported period, revenue was still tied to research collaboration activity, while the pipeline remained clinical-stage, so any weak program would be paused, stopped, or partnered, not divested.
- No commercial assets to sell
- Dog quadrant is empty
- Underperformers are handled pre-launch
No Dogs, Just $242.7M to Fund Bicycle’s Clinical Pipeline
In FY2025, Bicycle Therapeutics plc had 0 approved products and no product revenue, so the Dogs bucket is empty. The company’s $242.7 million cash, cash equivalents, and short-term investments support clinical work, not legacy product harvest.
| FY2025 metric | Value |
|---|---|
| Approved products | 0 |
| Product revenue | $0 |
| Cash and investments | $242.7 million |
| Dogs segment | None |
Question Marks
BT7455, preclinical EphA2/CD137 TICA
BT7455 is a preclinical EphA2/CD137 TICA, so it sits in the Question Mark bucket: high scientific ambition, but no human clinical proof yet. Its market case is still theoretical because preclinical assets have not shown efficacy or safety in patients, so revenue potential is unproven. Upside exists if it reaches clinic, but today the share base is effectively zero.
Anti-infectives collaboration
In FY2025, Bicycle Therapeutics had 0 disclosed dominant anti-infective assets, so this collaboration sits outside its core oncology base and fits a classic question mark. Anti-infectives can be a multibillion-dollar market, but without a lead program or meaningful disclosed share, the upside is still unproven. If the collaboration turns into a named clinical asset, it could shift fast; if not, it stays a low-share bet.
Cardiovascular collaboration
In FY2025 and into 2026, Bicycle Therapeutics plc’s cardiovascular collaboration stays a question mark: it is still exploratory, not a commercial business. The area could scale into a star if human validation and partner data come through, but today it has no proven revenue base. That leaves upside large, but risk high.
Respiratory collaboration
Respiratory collaboration stays a scale play, but Bicycle Therapeutics plc is still early and partner-led in FY2025, with no disclosed market share or market leadership. That puts it in the invest-or-exit zone: high upside if a partner moves fast, but weak control if data or funding slip.
- FY2025: no disclosed leadership
- Partner-led, not commercial
- Scale is possible, but unproven
Other undisclosed Bicycle peptide discovery targets
Other undisclosed Bicycle peptide discovery targets stay in the Question Marks box because they are still early discovery bets with no public clinical data. Bicycle Therapeutics plc kept adding new target ideas across oncology and other disease areas, so these programs can grow fast, but most will only move out of this quadrant after human data or a licensing deal.
- Early-stage, high-upside pipeline
- Multiple disease areas, still undisclosed
- Needs clinical proof or partner support
Bicycle Therapeutics’ early-stage pipeline remains a question mark
Bicycle Therapeutics plc’s question marks in FY2025 stayed early and unproven: BT7455 was still preclinical, while anti-infective, cardiovascular, and respiratory programs had no disclosed clinical share or revenue base. The upside is real, but it still depends on human data, partner backing, and funding.
| Area | FY2025 status | BCG view |
|---|---|---|
| BT7455 | Preclinical | Question Mark |
| Anti-infective | No disclosed share | Question Mark |
| Cardiovascular | Exploratory | Question Mark |
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.